Standardized Dosing Regimen for IMJUDO in uHCC

For adult patients with unresectable hepatocellular carcinoma (uHCC) weighing 30 kg or more, IMJUDO is administered as a single 300 mg intravenous infusion, followed by durvalumab 1,500 mg on the same day (Cycle 1, Day 1). Patients under 30 kg receive IMJUDO at 4 mg/kg and durvalumab at 20 mg/kg. After the initial combination, durvalumab monotherapy continues every four weeks until disease progression or unacceptable toxicity. IMJUDO must be diluted and infused over 60 minutes, with specific preparation and administration protocols. Dose modifications for adverse reactions are detailed in the prescribing information.